Phase I-II study of Genasense (Bcl-2 Antisense Oligonucleotide) in Patients With Advanced Chronic Lymphocytic Leukemia

Reviewer: Julie Draznin Maltzman, MD
OncoLink
Ultima Vez Modificado: 7 de diciembre del 2002

Translation for this article does not exist